News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrimack Pharmaceuticals Inc. (MACK) Initiates Phase 1 Clinical Study Of MM-398 In Combination With Cyclophosphamide For Pediatric Solid Tumors


1/23/2014 9:37:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Jan. 23, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced enrollment of its first patient in a Phase 1 dose-escalating clinical study of MM-398 in conjunction with cyclophosphamide for the treatment of pediatric solid tumors. MM-398 is a stable nanoliposomal irinotecan that is designed to exploit leaky tumor vasculature for enhanced drug delivery to tumors.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES